IMAC Holdings Inc

IMAC Holdings, Inc. provides medical services through integrated medicine and chiropractic regeneration centers. Its services include medical treatments, regenerative medicine, physical medicine, physical therapy, spinal decompression and chiropractic manipulation. The company was founded by Matthew C. Wallis, Jason William Brame and Jeffrey S. Ervin in August 2000 and is headquartered in Brentwood, TN.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IMAC Holdings, Inc. provides medical services through integrated medicine and chiropractic regeneration centers. Its services include medical treatments, regenerative medicine, physical medicine, physical therapy, spinal decompression and chiropractic manipulation. The company was founded by Matthew C. Wallis, Jason William Brame and Jeffrey S. Ervin in August 2000 and is headquartered in Franklin, TN.

The stock price of IMAC Holdings Inc (NASDAQ: IMAC) has increased by 23.53% as it went from a previous close of $1.19 to $1.47. This is why.

IMAC Stock Price Increases 23.97%: Why It Happened

BRENTWOOD, Tenn., Dec. 30, 2020 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or the “Company”), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, announces it completed the first infusion of its investigational compound utilizing umbilical cord-derived allogenic mesenchymal stem cells in its Phase 1 clinical trial for the treatment of bradykinesia, or the gradual slowing and loss of spontaneous body movement, due to Parkinson's disease.

IMAC Holdings Completes First Infusion of Stem Cells in Clinical Study for the Treatment of Bradykinesia Due to Parkinson's Disease

BRENTWOOD, Tenn., Dec. 04, 2020 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or the “Company”), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today announces the United States Small Business Administration (the “SBA”) has confirmed a complete waiver of a $1.69 million Payroll Protection Plan (“PPP”) promissory note issued by IMAC earlier this year. In the spring of 2020, as a result of the COVID-19 pandemic IMAC was forced to temporarily close three clinics under governor's orders and furlough or terminate 27% of its workforce. With the assistance of the PPP loan, as of September 30, 2020, 98% of IMAC's full and part-time workforce returned to work for IMAC.

IMAC Holdings Receives Forgiveness of $1.69 Million PPP Loan

BRENTWOOD, Tenn, Nov. 30, 2020 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or “the Company”), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today announces that it has received a letter from The Nasdaq Stock Market LLC ("Nasdaq") that IMAC has regained compliance with Nasdaq's minimum bid price for continued listing on the Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(a)(2).

IMAC Holdings, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement

BRENTWOOD, Tenn, Nov. 13, 2020 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or “the Company”), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today announces that management will participate in the Virtual Fall Investor Summit November 16-18, 2020.

IMAC Holdings, Inc. To Participate in the Virtual Fall Investor Summit on November 16-18, 2020

Financial performance improves sequentially with record billable patient visits and highlights strong operational and fiscal management despite continued COVID-19 impact

IMAC Holdings Reports Third Quarter 2020 Financial Results

BRENTWOOD, Tenn, Nov. 11, 2020 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or “the Company”), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today announces the acquisition of Lockwood Chiropractic in Webster Groves, Mo.

IMAC Holdings, Inc. Expands Missouri Footprint with Acquisition of Lockwood Chiropractic in Webster Groves

BRENTWOOD, Tenn, Nov. 05, 2020 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or “the Company”), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today announces it is opening enrollment in its Phase 1 clinical trial for its investigational compound utilizing umbilical cord-derived allogenic mesenchymal stem cells for the treatment of bradykinesia, or the gradual slowing and loss of spontaneous body movement, due to Parkinson's disease.

IMAC Holdings, Inc. Announces Opening Enrollment in Its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson's Disease

BRENTWOOD, Tenn., Nov. 02, 2020 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or “the Company”), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today announces the addition of Maurice “Mo” Evans, Michael Pruitt, and Cary Sucoff as independent directors to IMAC's board of directors (the “Board”).

IMAC Holdings, Inc. Adds Three Distinguished Executives to its Board of Directors

BRENTWOOD, Tenn and BIRMINGHAM, Mich., Sept.  23, 2020  (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today announced a partnership with Birmingham, Michigan-based Safe Balance, LLC to implement multi-factorial fall risk assessment services for individuals with balance deficiencies.

IMAC Holdings, Inc. Partners with Safe Balance, LLC to Provide Services that Improve Balance for the Reduction of Fall Risk

BRENTWOOD, Tenn., Sept.  15, 2020  (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today announced an update of IMAC’s service locations.

IMAC Holdings Announces Update to Service Locations

BRENTWOOD, Tenn., Aug.  25, 2020  (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (the “Company” or “IMAC”), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today announced that Jeff Ervin, President and Chief Executive Officer, will give a virtual corporate presentation at the LD Micro 500 taking place online on Tuesday, September 1, 2020 at 9:00 AM ET followed by a live Q&A session with registered investors and other conference attendees.

IMAC Holdings to Present at the LD Micro 500 Virtual Conference on September 1, 2020

BRENTWOOD, Tenn., Aug.  14, 2020  (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or the “Company”), a provider of innovative medical advancements and care, specializing in regenerative rehabilitation treatments without the use of surgery or opioids, today announces its financial results for its second quarter ended June 30, 2020.

IMAC Holdings Reports Second Quarter 2020 Financial Results

BRENTWOOD, Tenn., Aug.  05, 2020  (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (the “Company” or “IMAC”), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today announced the United States Food and Drug Administration (the “FDA”) approved its investigational new drug application, which IMAC submitted in May 2020, for the use of umbilical cord-derived allogenic mesenchymal stem cells for the treatment of bradykinesia, or the gradual loss and slowing down of spontaneous body movement, due to Parkinson’s disease.

IMAC Holdings Receives FDA Authorization to Initiate Clinical Study of Its Umbilical Cord-Derived Allogenic Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson’s Disease

BRENTWOOD, Tenn., July  27, 2020  (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (the “Company” or “IMAC”), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today announced it sold real estate in Lexington, Kentucky, on July 24, 2020, in a sale-leaseback transaction for a sale price of $1,300,000. The sale of the property will eliminate $1,232,000 in liability for the Company. Simultaneous with the sale, the Company also entered into a five-year lease of the property with the purchaser of the property.

IMAC Regeneration Centers Sells Lexington Property for $1.3M in Sale-Leaseback Transaction

BRENTWOOD, Tenn., June  18, 2020  (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today announced it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 1,764,000 shares of common stock, par value $0.001 per share, at an offering price of $1.50 per share, pursuant to a registered direct offering. The gross proceeds of the offering will be approximately $2,646,000, before deducting fees and other estimated offering expenses. The closing of the registered direct offering is expected to take place on or about June 22, 2020, subject to the satisfaction of customary closing conditions.

IMAC Holdings Prices $2.65 Million Common Stock Offering

BRENTWOOD, Tenn., June  17, 2020  (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today announced results from an extensive internal analysis of treatment outcomes for musculoskeletal conditions performed at IMAC Regeneration Centers, which showed approximately 81% of IMAC patients reported improvement in movement.

IMAC Regeneration Centers Analysis Shows 81% of Patients Report Improvement in Functional Outcomes from Treatment of Musculoskeletal Conditions

BRENTWOOD, Tenn, May  14, 2020  (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or the “Company”), a provider of Innovative Medical Advancements and Care, specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today announces first quarter financial results ending March 31, 2020.

IMAC Holdings Reports First Quarter 2020 Financial Results, Including 19% Growth of Patient Services Revenue Compared to 2019

BRENTWOOD, Tenn, March  26, 2020  (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or the “Company”), a provider of Innovative Medical Advancements and Care, specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today announces financial results for the year ending December 31, 2019.

IMAC Holdings Reports 2019 Financial Results, Including 126% Growth of  Patient Services Revenue Compared to 2018

With several states in the U.S. ordering residents to shelter in place to help reduce the spread of the coronavirus, the demand for telehealth services for patients staying at home is likely to surge in the coming days.

IMAC Skyrockets On Launch Of Telehealth Services For Patients Sheltering In Place

BRENTWOOD, Tenn, March  24, 2020  (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (the “Company” or “IMAC”), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today announced it has implemented a new telehealth option to allow active care patients direct and consistent communications with IMAC medical professionals even while observing “shelter in place” status.

IMAC Launches New Telehealth Options to Maintain Consistent Communications with Active Care Patients Choosing to “Shelter in Place”

BRENTWOOD, Tenn, Feb.  12, 2020  (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today announced the appointment of Gerard M. Hayden, Jr. to its Board of Directors (the “Board”).

IMAC Welcomes Financial Industry Veteran Gerard M. Hayden, Jr.

BRENTWOOD, Tenn., Dec.  31, 2019  (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (the “Company” or “IMAC”), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today announced CEO, Jeff Ervin, issued a Letter to Shareholders. Contents of the letter follow:

News for IMAC Holdings Inc Stock (IMAC)